Literature DB >> 7786580

Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.

S L Orloff1, C I Bandea, M S Kennedy, G P Allaway, P J Maddon, J S McDougal.   

Abstract

Primary isolates of human immunodeficiency virus type 1 (HIV-1) were obtained by coculture of peripheral blood lymphocytes (PBLs) from HIV-1-infected people with PBLs from uninfected donors. These viral stocks tend to be resistant to neutralization/inactivation by soluble CD4 (sCD4). When these stocks were passed through the T cell line C8166, virus stocks emerged that were sensitive to sCD4. Pre- and post-C8166 stocks maintained their sCD4-resistant and -sensitive phenotypes, respectively, with further passage in PBLs. Pre- and post-C8166 stocks were biologically cloned by two cycles of limiting dilution. The majority (14 of 17) of pre-C8166 clones were sCD4 resistant, and, conversely, the majority of post-C8166 clones (11 of 12) were sensitive to sCD4. Nucleotide and predicted amino acid sequence analysis in the env (gp120) region revealed a limited number of differences between the clones. The only differences that sorted with biological phenotype were in the first constant (C1) region of gp120. Adaptation to growth in C8166 cells and conversion from the sCD4-resistant to the sCD4-sensitive phenotype represent the emergence to prominence of viral species in the pre-C8166 stock that have a replication advantage in C8166 coincident with increased sensitivity to sCD4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786580     DOI: 10.1089/aid.1995.11.335

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.

Authors:  J E Johnson; M J Schnell; L Buonocore; J K Rose
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions.

Authors:  Andrés Finzi; Shi-Hua Xiang; Beatriz Pacheco; Liping Wang; Jessica Haight; Aemro Kassa; Brenda Danek; Marie Pancera; Peter D Kwong; Joseph Sodroski
Journal:  Mol Cell       Date:  2010-03-12       Impact factor: 17.970

6.  Residues in the membrane-spanning domain core modulate conformation and fusogenicity of the HIV-1 envelope glycoprotein.

Authors:  Liang Shang; Eric Hunter
Journal:  Virology       Date:  2010-06-01       Impact factor: 3.616

7.  Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.

Authors:  E Hogervorst; J de Jong; A van Wijk; M Bakker; M Valk; P Nara; J Goudsmit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

Authors:  J York; K E Follis; M Trahey; P N Nyambi; S Zolla-Pazner; J H Nunberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

Authors:  A Trkola; T Ketas; V N Kewalramani; F Endorf; J M Binley; H Katinger; J Robinson; D R Littman; J P Moore
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

10.  Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

Authors:  J Lewis; P Balfe; C Arnold; S Kaye; R S Tedder; J A McKeating
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.